Two drugs have been launched: Sensipar/Mimpra cinacalcet (Amgen/NPS) is a PAM of calcium-sensing receptor (CaSR) for hyperparathyroidism treatment; Selzentry/Celsentri maraviroc (Pfizer) is a NAM of C-C chemokine receptor type 5 (CCR5) for human immunodeficiency virus (HIV) therapy. The gene discussed is CASR; the disease is hyperparathyroidism.